U.S. market Closed. Opens in 5 hours 26 minutes

AGIO | Agios Pharmaceuticals, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for AGIO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is strong.

Valuation (29%)

Company Industry
P/E Ratio (TTM) -7.02 -22.01
PEG Ratio (TTM) 2.46 15.69
P/S Ratio (TTM) 81.94 48.43
P/B Ratio (TTM) 3.88 18.71
P/FCF Ratio (TTM) -7.89 -2.79
Price to 5YR AVG Earnings Ratio 30.50 -3.21
Price to 5YR AVG FCF Ratio -7.49 -8.75

Profitability (0%)

Company Industry
ROA (TTM) -47.21% -5.02%
ROE (TTM) -47.05% 16.95%
Net Profit Margin (TTM) -1,165.69% -1,552.13%
ROIC 5YR AVG -46.62% 14.51%

Growth (50%)

4QTR AVG 3YR AVG 5YR AVG
EPS -3.59% 221.05% 38.52%
Revenue 6.68% -0.92% 17.12%
Net Income -4.22% 193.19% 20.53%
Cash Flow -5.10% -13.43% -2.39%

Health (61%)

Company Industry
Current Ratio (TTM) 10.09 6.08
Quick Ratio (TTM) 9.71 5.80
D/E Ratio (TTM) 0.10 -15.32
Interest Coverage (TTM) N/A -1.96
Piotroski F-Score 3 5
Altman Z-Score 11.20 13.86
LTL to 5YR AVG FCF -0.17 0.16
Shares Outstanding Growth 5YR AVG -0.14% 128.58%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙